CN108013299A - 补充体能饮料 - Google Patents
补充体能饮料 Download PDFInfo
- Publication number
- CN108013299A CN108013299A CN201610931623.XA CN201610931623A CN108013299A CN 108013299 A CN108013299 A CN 108013299A CN 201610931623 A CN201610931623 A CN 201610931623A CN 108013299 A CN108013299 A CN 108013299A
- Authority
- CN
- China
- Prior art keywords
- vitamin
- acid
- taurine
- glucose
- sodium chloride
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000013589 supplement Substances 0.000 title claims abstract description 25
- 235000013361 beverage Nutrition 0.000 title claims abstract description 15
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 claims abstract description 90
- GHOKWGTUZJEAQD-ZETCQYMHSA-N (D)-(+)-Pantothenic acid Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 claims abstract description 63
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 claims abstract description 56
- 229960003080 taurine Drugs 0.000 claims abstract description 45
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims abstract description 41
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims abstract description 38
- 239000008103 glucose Substances 0.000 claims abstract description 35
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims abstract description 34
- 239000011726 vitamin B6 Substances 0.000 claims abstract description 34
- GHOKWGTUZJEAQD-UHFFFAOYSA-N Chick antidermatitis factor Natural products OCC(C)(C)C(O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-UHFFFAOYSA-N 0.000 claims abstract description 31
- 239000011713 pantothenic acid Substances 0.000 claims abstract description 31
- 229940055726 pantothenic acid Drugs 0.000 claims abstract description 31
- 235000019161 pantothenic acid Nutrition 0.000 claims abstract description 31
- 235000001968 nicotinic acid Nutrition 0.000 claims abstract description 28
- 229960003512 nicotinic acid Drugs 0.000 claims abstract description 28
- 239000011664 nicotinic acid Substances 0.000 claims abstract description 28
- 239000011691 vitamin B1 Substances 0.000 claims abstract description 23
- 239000011715 vitamin B12 Substances 0.000 claims abstract description 23
- 239000011780 sodium chloride Substances 0.000 claims abstract description 20
- 235000002639 sodium chloride Nutrition 0.000 claims abstract description 20
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims abstract description 19
- FDJOLVPMNUYSCM-WZHZPDAFSA-L cobalt(3+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+3].N#[C-].N([C@@H]([C@]1(C)[N-]\C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C(\C)/C1=N/C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C\C1=N\C([C@H](C1(C)C)CCC(N)=O)=C/1C)[C@@H]2CC(N)=O)=C\1[C@]2(C)CCC(=O)NC[C@@H](C)OP([O-])(=O)O[C@H]1[C@@H](O)[C@@H](N2C3=CC(C)=C(C)C=C3N=C2)O[C@@H]1CO FDJOLVPMNUYSCM-WZHZPDAFSA-L 0.000 claims abstract description 18
- ZUFQODAHGAHPFQ-UHFFFAOYSA-N pyridoxine hydrochloride Chemical compound Cl.CC1=NC=C(CO)C(CO)=C1O ZUFQODAHGAHPFQ-UHFFFAOYSA-N 0.000 claims abstract description 18
- 235000016709 nutrition Nutrition 0.000 claims abstract description 14
- 239000000463 material Substances 0.000 claims abstract description 13
- 230000035764 nutrition Effects 0.000 claims abstract description 12
- 239000002994 raw material Substances 0.000 claims abstract description 11
- 235000010241 potassium sorbate Nutrition 0.000 claims abstract description 7
- CHHHXKFHOYLYRE-UHFFFAOYSA-M 2,4-Hexadienoic acid, potassium salt (1:1), (2E,4E)- Chemical compound [K+].CC=CC=CC([O-])=O CHHHXKFHOYLYRE-UHFFFAOYSA-M 0.000 claims abstract description 6
- 239000004302 potassium sorbate Substances 0.000 claims abstract description 6
- 229940069338 potassium sorbate Drugs 0.000 claims abstract description 6
- 229960002668 sodium chloride Drugs 0.000 claims abstract description 5
- 229960001031 glucose Drugs 0.000 claims abstract description 3
- DPJRMOMPQZCRJU-UHFFFAOYSA-M thiamine hydrochloride Chemical compound Cl.[Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N DPJRMOMPQZCRJU-UHFFFAOYSA-M 0.000 claims abstract 5
- 239000000203 mixture Substances 0.000 claims description 4
- 230000000694 effects Effects 0.000 abstract description 25
- 235000019156 vitamin B Nutrition 0.000 abstract description 8
- 239000011720 vitamin B Substances 0.000 abstract description 8
- 206010016256 fatigue Diseases 0.000 abstract description 6
- 229930003270 Vitamin B Natural products 0.000 abstract description 4
- 230000005195 poor health Effects 0.000 abstract description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 20
- JZRWCGZRTZMZEH-UHFFFAOYSA-N thiamine Chemical compound CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N JZRWCGZRTZMZEH-UHFFFAOYSA-N 0.000 description 17
- 229940088594 vitamin Drugs 0.000 description 14
- 229930003231 vitamin Natural products 0.000 description 14
- 235000013343 vitamin Nutrition 0.000 description 14
- 239000011782 vitamin Substances 0.000 description 14
- 150000003722 vitamin derivatives Chemical class 0.000 description 12
- 230000036541 health Effects 0.000 description 11
- 238000001727 in vivo Methods 0.000 description 11
- 210000004369 blood Anatomy 0.000 description 10
- 239000008280 blood Substances 0.000 description 10
- 235000013305 food Nutrition 0.000 description 10
- 230000006870 function Effects 0.000 description 9
- 210000001519 tissue Anatomy 0.000 description 9
- 230000033228 biological regulation Effects 0.000 description 8
- 230000015572 biosynthetic process Effects 0.000 description 8
- 150000001720 carbohydrates Chemical class 0.000 description 8
- 235000014633 carbohydrates Nutrition 0.000 description 8
- 210000004027 cell Anatomy 0.000 description 8
- 210000004185 liver Anatomy 0.000 description 8
- 239000000047 product Substances 0.000 description 8
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 7
- 230000004060 metabolic process Effects 0.000 description 7
- 235000018102 proteins Nutrition 0.000 description 7
- 108090000623 proteins and genes Proteins 0.000 description 7
- 102000004169 proteins and genes Human genes 0.000 description 7
- LXNHXLLTXMVWPM-UHFFFAOYSA-N pyridoxine Chemical compound CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 description 7
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 6
- 235000019197 fats Nutrition 0.000 description 6
- RADKZDMFGJYCBB-UHFFFAOYSA-N pyridoxal hydrochloride Natural products CC1=NC=C(CO)C(C=O)=C1O RADKZDMFGJYCBB-UHFFFAOYSA-N 0.000 description 6
- BAWFJGJZGIEFAR-NNYOXOHSSA-N NAD zwitterion Chemical compound NC(=O)C1=CC=C[N+]([C@H]2[C@@H]([C@H](O)[C@@H](COP([O-])(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 BAWFJGJZGIEFAR-NNYOXOHSSA-N 0.000 description 5
- 239000002253 acid Substances 0.000 description 5
- 235000001014 amino acid Nutrition 0.000 description 5
- 150000001413 amino acids Chemical class 0.000 description 5
- 235000015165 citric acid Nutrition 0.000 description 5
- 239000005515 coenzyme Substances 0.000 description 5
- 210000004209 hair Anatomy 0.000 description 5
- 238000004519 manufacturing process Methods 0.000 description 5
- 229950006238 nadide Drugs 0.000 description 5
- 210000005036 nerve Anatomy 0.000 description 5
- 235000015097 nutrients Nutrition 0.000 description 5
- 208000024891 symptom Diseases 0.000 description 5
- 229960003495 thiamine Drugs 0.000 description 5
- 208000031845 Pernicious anaemia Diseases 0.000 description 4
- LCTONWCANYUPML-UHFFFAOYSA-N Pyruvic acid Chemical compound CC(=O)C(O)=O LCTONWCANYUPML-UHFFFAOYSA-N 0.000 description 4
- 210000001124 body fluid Anatomy 0.000 description 4
- 239000010839 body fluid Substances 0.000 description 4
- 238000011049 filling Methods 0.000 description 4
- 235000012054 meals Nutrition 0.000 description 4
- 210000003205 muscle Anatomy 0.000 description 4
- 239000011570 nicotinamide Substances 0.000 description 4
- 229960003966 nicotinamide Drugs 0.000 description 4
- 235000005152 nicotinamide Nutrition 0.000 description 4
- NHZMQXZHNVQTQA-UHFFFAOYSA-N pyridoxamine Chemical compound CC1=NC=C(CO)C(CN)=C1O NHZMQXZHNVQTQA-UHFFFAOYSA-N 0.000 description 4
- 238000003786 synthesis reaction Methods 0.000 description 4
- -1 taurine Propylhomoserin sulfurous acid carboxylic acid Chemical class 0.000 description 4
- 235000019157 thiamine Nutrition 0.000 description 4
- 239000011721 thiamine Substances 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 102000040350 B family Human genes 0.000 description 3
- 108091072128 B family Proteins 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 229920002527 Glycogen Polymers 0.000 description 3
- 208000013016 Hypoglycemia Diseases 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 description 3
- 206010029400 Nicotinic acid deficiency Diseases 0.000 description 3
- 208000002141 Pellagra Diseases 0.000 description 3
- 206010047700 Vomiting Diseases 0.000 description 3
- 239000003242 anti bacterial agent Substances 0.000 description 3
- 229940088710 antibiotic agent Drugs 0.000 description 3
- 208000010668 atopic eczema Diseases 0.000 description 3
- 238000009835 boiling Methods 0.000 description 3
- 230000023852 carbohydrate metabolic process Effects 0.000 description 3
- 239000001569 carbon dioxide Substances 0.000 description 3
- 229910002092 carbon dioxide Inorganic materials 0.000 description 3
- 239000013078 crystal Substances 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 210000003743 erythrocyte Anatomy 0.000 description 3
- 229940096919 glycogen Drugs 0.000 description 3
- 230000002218 hypoglycaemic effect Effects 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 230000003340 mental effect Effects 0.000 description 3
- 230000002503 metabolic effect Effects 0.000 description 3
- VUZPPFZMUPKLLV-UHFFFAOYSA-N methane;hydrate Chemical compound C.O VUZPPFZMUPKLLV-UHFFFAOYSA-N 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 230000001681 protective effect Effects 0.000 description 3
- 150000003839 salts Chemical class 0.000 description 3
- 210000003491 skin Anatomy 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 231100000419 toxicity Toxicity 0.000 description 3
- 230000001988 toxicity Effects 0.000 description 3
- 229940046001 vitamin b complex Drugs 0.000 description 3
- 229940011671 vitamin b6 Drugs 0.000 description 3
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 2
- 206010019233 Headaches Diseases 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- 108010031311 Intramolecular Transferases Proteins 0.000 description 2
- 102000005385 Intramolecular Transferases Human genes 0.000 description 2
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 2
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 2
- 208000027530 Meniere disease Diseases 0.000 description 2
- 229910019142 PO4 Inorganic materials 0.000 description 2
- 208000002193 Pain Diseases 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 2
- KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 description 2
- 241000235342 Saccharomycetes Species 0.000 description 2
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 2
- 229930003451 Vitamin B1 Natural products 0.000 description 2
- 125000002252 acyl group Chemical group 0.000 description 2
- GZCGUPFRVQAUEE-SLPGGIOYSA-N aldehydo-D-glucose Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O GZCGUPFRVQAUEE-SLPGGIOYSA-N 0.000 description 2
- 230000000172 allergic effect Effects 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 239000002585 base Substances 0.000 description 2
- 230000017531 blood circulation Effects 0.000 description 2
- 210000004958 brain cell Anatomy 0.000 description 2
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 description 2
- 229910001424 calcium ion Inorganic materials 0.000 description 2
- 210000004413 cardiac myocyte Anatomy 0.000 description 2
- 239000000496 cardiotonic agent Substances 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 235000019504 cigarettes Nutrition 0.000 description 2
- 239000000470 constituent Substances 0.000 description 2
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 2
- 235000018417 cysteine Nutrition 0.000 description 2
- 238000006114 decarboxylation reaction Methods 0.000 description 2
- 238000000354 decomposition reaction Methods 0.000 description 2
- 238000001784 detoxification Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 239000003792 electrolyte Substances 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 238000006911 enzymatic reaction Methods 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 description 2
- 231100000869 headache Toxicity 0.000 description 2
- 230000004217 heart function Effects 0.000 description 2
- QWPPOHNGKGFGJK-UHFFFAOYSA-N hypochlorous acid Chemical compound ClO QWPPOHNGKGFGJK-UHFFFAOYSA-N 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 238000007689 inspection Methods 0.000 description 2
- 150000002500 ions Chemical class 0.000 description 2
- 239000000644 isotonic solution Substances 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 235000013372 meat Nutrition 0.000 description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- 230000001590 oxidative effect Effects 0.000 description 2
- 239000010452 phosphate Substances 0.000 description 2
- 230000035479 physiological effects, processes and functions Effects 0.000 description 2
- 231100000614 poison Toxicity 0.000 description 2
- 239000001103 potassium chloride Substances 0.000 description 2
- 235000011164 potassium chloride Nutrition 0.000 description 2
- 230000035935 pregnancy Effects 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 229960003581 pyridoxal Drugs 0.000 description 2
- 235000008164 pyridoxal Nutrition 0.000 description 2
- 239000011674 pyridoxal Substances 0.000 description 2
- 235000008151 pyridoxamine Nutrition 0.000 description 2
- 239000011699 pyridoxamine Substances 0.000 description 2
- 235000008160 pyridoxine Nutrition 0.000 description 2
- 239000011677 pyridoxine Substances 0.000 description 2
- 229940107700 pyruvic acid Drugs 0.000 description 2
- 230000029058 respiratory gaseous exchange Effects 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 230000001954 sterilising effect Effects 0.000 description 2
- 238000004659 sterilization and disinfection Methods 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 239000011593 sulfur Substances 0.000 description 2
- 229910052717 sulfur Inorganic materials 0.000 description 2
- 235000019605 sweet taste sensations Nutrition 0.000 description 2
- 230000002194 synthesizing effect Effects 0.000 description 2
- 239000003440 toxic substance Substances 0.000 description 2
- 238000007514 turning Methods 0.000 description 2
- 235000010374 vitamin B1 Nutrition 0.000 description 2
- 239000011708 vitamin B3 Substances 0.000 description 2
- 235000019158 vitamin B6 Nutrition 0.000 description 2
- 230000008673 vomiting Effects 0.000 description 2
- OGNSCSPNOLGXSM-UHFFFAOYSA-N (+/-)-DABA Natural products NCCC(N)C(O)=O OGNSCSPNOLGXSM-UHFFFAOYSA-N 0.000 description 1
- DWNBOPVKNPVNQG-LURJTMIESA-N (2s)-4-hydroxy-2-(propylamino)butanoic acid Chemical compound CCCN[C@H](C(O)=O)CCO DWNBOPVKNPVNQG-LURJTMIESA-N 0.000 description 1
- GDSOZVZXVXTJMI-SNAWJCMRSA-N (e)-1-methylbut-1-ene-1,2,4-tricarboxylic acid Chemical compound OC(=O)C(/C)=C(C(O)=O)\CCC(O)=O GDSOZVZXVXTJMI-SNAWJCMRSA-N 0.000 description 1
- LDHMAVIPBRSVRG-UHFFFAOYSA-O 1-methylnicotinamide Chemical compound C[N+]1=CC=CC(C(N)=O)=C1 LDHMAVIPBRSVRG-UHFFFAOYSA-O 0.000 description 1
- KPGXRSRHYNQIFN-UHFFFAOYSA-L 2-oxoglutarate(2-) Chemical compound [O-]C(=O)CCC(=O)C([O-])=O KPGXRSRHYNQIFN-UHFFFAOYSA-L 0.000 description 1
- LJUQGASMPRMWIW-UHFFFAOYSA-N 5,6-dimethylbenzimidazole Chemical compound C1=C(C)C(C)=CC2=C1NC=N2 LJUQGASMPRMWIW-UHFFFAOYSA-N 0.000 description 1
- 108010013043 Acetylesterase Proteins 0.000 description 1
- 208000002874 Acne Vulgaris Diseases 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- 240000007087 Apium graveolens Species 0.000 description 1
- 241000432824 Asparagus densiflorus Species 0.000 description 1
- 206010004542 Bezoar Diseases 0.000 description 1
- 235000010149 Brassica rapa subsp chinensis Nutrition 0.000 description 1
- 235000000536 Brassica rapa subsp pekinensis Nutrition 0.000 description 1
- 241000499436 Brassica rapa subsp. pekinensis Species 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 206010008092 Cerebral artery thrombosis Diseases 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 208000002330 Congenital Heart Defects Diseases 0.000 description 1
- 102100026278 Cysteine sulfinic acid decarboxylase Human genes 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- LKDRXBCSQODPBY-VRPWFDPXSA-N D-fructopyranose Chemical compound OCC1(O)OC[C@@H](O)[C@@H](O)[C@@H]1O LKDRXBCSQODPBY-VRPWFDPXSA-N 0.000 description 1
- 206010012289 Dementia Diseases 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 206010013911 Dysgeusia Diseases 0.000 description 1
- 206010013935 Dysmenorrhoea Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 208000001034 Frostbite Diseases 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- 101000855583 Homo sapiens Cysteine sulfinic acid decarboxylase Proteins 0.000 description 1
- 206010020651 Hyperkinesia Diseases 0.000 description 1
- 208000000269 Hyperkinesis Diseases 0.000 description 1
- 208000031226 Hyperlipidaemia Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- LEVWYRKDKASIDU-IMJSIDKUSA-N L-cystine Chemical compound [O-]C(=O)[C@@H]([NH3+])CSSC[C@H]([NH3+])C([O-])=O LEVWYRKDKASIDU-IMJSIDKUSA-N 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- 208000002720 Malnutrition Diseases 0.000 description 1
- 208000019255 Menstrual disease Diseases 0.000 description 1
- 208000019695 Migraine disease Diseases 0.000 description 1
- 208000007101 Muscle Cramp Diseases 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 235000000365 Oenanthe javanica Nutrition 0.000 description 1
- 206010068319 Oropharyngeal pain Diseases 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 201000007100 Pharyngitis Diseases 0.000 description 1
- 244000046052 Phaseolus vulgaris Species 0.000 description 1
- 235000010627 Phaseolus vulgaris Nutrition 0.000 description 1
- 208000004880 Polyuria Diseases 0.000 description 1
- 206010036618 Premenstrual syndrome Diseases 0.000 description 1
- 208000010378 Pulmonary Embolism Diseases 0.000 description 1
- 206010037423 Pulmonary oedema Diseases 0.000 description 1
- 235000013559 Schnittsellerie Nutrition 0.000 description 1
- 208000006981 Skin Abnormalities Diseases 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- FZWLAAWBMGSTSO-UHFFFAOYSA-N Thiazole Chemical group C1=CSC=N1 FZWLAAWBMGSTSO-UHFFFAOYSA-N 0.000 description 1
- 208000009205 Tinnitus Diseases 0.000 description 1
- 206010044565 Tremor Diseases 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- 239000006035 Tryptophane Substances 0.000 description 1
- 229930003779 Vitamin B12 Natural products 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- NVJHHSJKESILSZ-UHFFFAOYSA-N [Co].N1C(C=C2N=C(C=C3NC(=C4)C=C3)C=C2)=CC=C1C=C1C=CC4=N1 Chemical class [Co].N1C(C=C2N=C(C=C3NC(=C4)C=C3)C=C2)=CC=C1C=C1C=CC4=N1 NVJHHSJKESILSZ-UHFFFAOYSA-N 0.000 description 1
- XJLXINKUBYWONI-DQQFMEOOSA-N [[(2r,3r,4r,5r)-5-(6-aminopurin-9-yl)-3-hydroxy-4-phosphonooxyoxolan-2-yl]methoxy-hydroxyphosphoryl] [(2s,3r,4s,5s)-5-(3-carbamoylpyridin-1-ium-1-yl)-3,4-dihydroxyoxolan-2-yl]methyl phosphate Chemical compound NC(=O)C1=CC=C[N+]([C@@H]2[C@H]([C@@H](O)[C@H](COP([O-])(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](OP(O)(O)=O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 XJLXINKUBYWONI-DQQFMEOOSA-N 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- LPQOADBMXVRBNX-UHFFFAOYSA-N ac1ldcw0 Chemical compound Cl.C1CN(C)CCN1C1=C(F)C=C2C(=O)C(C(O)=O)=CN3CCSC1=C32 LPQOADBMXVRBNX-UHFFFAOYSA-N 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 239000003929 acidic solution Substances 0.000 description 1
- 206010000496 acne Diseases 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 231100000570 acute poisoning Toxicity 0.000 description 1
- 210000000577 adipose tissue Anatomy 0.000 description 1
- 230000004103 aerobic respiration Effects 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 150000001299 aldehydes Chemical class 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 239000012670 alkaline solution Substances 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 230000037354 amino acid metabolism Effects 0.000 description 1
- 230000002929 anti-fatigue Effects 0.000 description 1
- 230000002558 anti-leprotic effect Effects 0.000 description 1
- 230000002460 anti-migrenic effect Effects 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 210000000941 bile Anatomy 0.000 description 1
- 235000019636 bitter flavor Nutrition 0.000 description 1
- 208000002352 blister Diseases 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 229960001948 caffeine Drugs 0.000 description 1
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000011712 cell development Effects 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 235000013339 cereals Nutrition 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 201000004709 chorioretinitis Diseases 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 239000010941 cobalt Substances 0.000 description 1
- 229910017052 cobalt Inorganic materials 0.000 description 1
- GUTLYIVDDKVIGB-UHFFFAOYSA-N cobalt atom Chemical compound [Co] GUTLYIVDDKVIGB-UHFFFAOYSA-N 0.000 description 1
- 229910001429 cobalt ion Inorganic materials 0.000 description 1
- XLJKHNWPARRRJB-UHFFFAOYSA-N cobalt(2+) Chemical compound [Co+2] XLJKHNWPARRRJB-UHFFFAOYSA-N 0.000 description 1
- ZGRKFKYTCMLCCF-UHFFFAOYSA-N cobalt;oxalonitrile Chemical compound [Co].N#CC#N ZGRKFKYTCMLCCF-UHFFFAOYSA-N 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- WUPRCGRRQUZFAB-DEGKJRJSSA-N corrin Chemical group N1C2CC\C1=C\C(CC/1)=N\C\1=C/C(CC\1)=N/C/1=C\C1=NC2CC1 WUPRCGRRQUZFAB-DEGKJRJSSA-N 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 229960003067 cystine Drugs 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 230000018044 dehydration Effects 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 239000003866 digestant Substances 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- 230000035619 diuresis Effects 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 235000013601 eggs Nutrition 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 235000020774 essential nutrients Nutrition 0.000 description 1
- 230000002964 excitative effect Effects 0.000 description 1
- 208000016253 exhaustion Diseases 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 235000019688 fish Nutrition 0.000 description 1
- 235000013373 food additive Nutrition 0.000 description 1
- 239000002778 food additive Substances 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 229960003692 gamma aminobutyric acid Drugs 0.000 description 1
- 210000004051 gastric juice Anatomy 0.000 description 1
- 229940093181 glucose injection Drugs 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 230000005831 heart abnormality Effects 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- 230000004727 humoral immunity Effects 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000004941 influx Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000013067 intermediate product Substances 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 125000000468 ketone group Chemical group 0.000 description 1
- 230000006651 lactation Effects 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 235000020997 lean meat Nutrition 0.000 description 1
- 230000004446 light reflex Effects 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 235000000824 malnutrition Nutrition 0.000 description 1
- 230000001071 malnutrition Effects 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 108010009674 methylaspartate mutase Proteins 0.000 description 1
- 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 description 1
- MZFOKIKEPGUZEN-FBMOWMAESA-N methylmalonyl-CoA Chemical compound O[C@@H]1[C@H](OP(O)(O)=O)[C@@H](COP(O)(=O)OP(O)(=O)OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCSC(=O)C(C(O)=O)C)O[C@H]1N1C2=NC=NC(N)=C2N=C1 MZFOKIKEPGUZEN-FBMOWMAESA-N 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 206010027599 migraine Diseases 0.000 description 1
- 208000030194 mouth disease Diseases 0.000 description 1
- 210000004165 myocardium Anatomy 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 210000004126 nerve fiber Anatomy 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 239000002858 neurotransmitter agent Substances 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 238000010606 normalization Methods 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 208000015380 nutritional deficiency disease Diseases 0.000 description 1
- 235000003715 nutritional status Nutrition 0.000 description 1
- 230000009965 odorless effect Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 150000002894 organic compounds Chemical class 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 210000001819 pancreatic juice Anatomy 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 230000008855 peristalsis Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 230000007096 poisonous effect Effects 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- CHHHXKFHOYLYRE-STWYSWDKSA-M potassium sorbate Chemical class [K+].C\C=C\C=C\C([O-])=O CHHHXKFHOYLYRE-STWYSWDKSA-M 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 238000001243 protein synthesis Methods 0.000 description 1
- 230000001107 psychogenic effect Effects 0.000 description 1
- 208000005333 pulmonary edema Diseases 0.000 description 1
- NGVDGCNFYWLIFO-UHFFFAOYSA-N pyridoxal 5'-phosphate Chemical compound CC1=NC=C(COP(O)(O)=O)C(C=O)=C1O NGVDGCNFYWLIFO-UHFFFAOYSA-N 0.000 description 1
- 125000000714 pyrimidinyl group Chemical group 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 210000001525 retina Anatomy 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 230000005808 skin problem Effects 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 235000011496 sports drink Nutrition 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- VNOYUJKHFWYWIR-ITIYDSSPSA-N succinyl-CoA Chemical compound O[C@@H]1[C@H](OP(O)(O)=O)[C@@H](COP(O)(=O)OP(O)(=O)OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCSC(=O)CCC(O)=O)O[C@H]1N1C2=NC=NC(N)=C2N=C1 VNOYUJKHFWYWIR-ITIYDSSPSA-N 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 210000004243 sweat Anatomy 0.000 description 1
- YXVCLPJQTZXJLH-UHFFFAOYSA-N thiamine(1+) diphosphate chloride Chemical compound [Cl-].CC1=C(CCOP(O)(=O)OP(O)(O)=O)SC=[N+]1CC1=CN=C(C)N=C1N YXVCLPJQTZXJLH-UHFFFAOYSA-N 0.000 description 1
- 201000004647 tinea pedis Diseases 0.000 description 1
- 231100000886 tinnitus Toxicity 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 239000011573 trace mineral Substances 0.000 description 1
- 235000013619 trace mineral Nutrition 0.000 description 1
- 238000012549 training Methods 0.000 description 1
- 238000006276 transfer reaction Methods 0.000 description 1
- 230000014616 translation Effects 0.000 description 1
- 230000001960 triggered effect Effects 0.000 description 1
- 229960004799 tryptophan Drugs 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 239000003071 vasodilator agent Substances 0.000 description 1
- 239000011345 viscous material Substances 0.000 description 1
- 235000019163 vitamin B12 Nutrition 0.000 description 1
- 239000011675 vitamin B5 Substances 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 238000004073 vulcanization Methods 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 235000015099 wheat brans Nutrition 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
- A23L2/38—Other non-alcoholic beverages
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Health & Medical Sciences (AREA)
- Nutrition Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
本发明给出了一种补充体能饮料,它是以葡萄糖、牛磺酸、维生素B1、维生素B6、维生素B12、烟酸、泛酸、氯化钠为原料,柠檬酸、山梨酸钾为辅料;共1种原料,7种营养强化剂,2种辅料。每5000ml饮料中各味成分的最佳重量为含葡萄糖:200g、牛磺酸:2.5g、维生素B1:15mg、维生素B6:7.5mg、维生素B12:9mg、烟酸:75mg、泛酸:10mg、氯化钠:5g。葡萄糖是人体必须的能量根本,本发明以葡萄糖为原料,并添加营养强化剂牛磺酸、维生素B1、维生素B6、维生素B12、烟酸、泛酸、氯化钠,可快速补充人体因长时间工作、剧烈运动、身体虚弱以及夏季大量出汗所缺失各种能量,对缓解身体疲惫感有着明显的作用。
Description
技术领域
本发明是一种功能性健康饮品,特别是一种以快速补充人体能量为出发点,将多种营养强化剂合理应用到本发明的配方中,能快速补充人体能量的功能性健康饮品。
背景技术
目前是市场上的功能饮料,其中含有咖啡因,多以“抗疲劳,补充能量和人体日常活动所需的营养成分”为主要作用。但是,运动医学专家指出,由于一些功能饮料中含有咖啡因等刺激中枢神经的成分,对于儿童来讲应该慎用。而普通成年人对功能饮料虽然可以不受限制地饮用,但也要注意一些特殊情况。比如运动饮料适合在强烈运动、人体大量流汗后饮用,其中的电解质和维生素可以迅速补充人体机能。但这类饮料并不适合在没有运动的情况下饮用,因为其中所含的钠元素会增加机体负担,引起心脏负荷加大、血压升高,因此,血压高的人群应当注意选择。这种对人体健康可能造成危害的功能饮料,与本身所宣传的健康理念是相悖的,也是不安全的。
发明内容
本发明要解决的问题是:为人们提供一种既可以快速补充人体所需的各种营养素,恢复体力和精力,并且还是安全无副作用的健康功能性饮品。
本发明的主要内容是:它是以葡萄糖、牛磺酸、维生素B1、维生素B6、维生素B12、烟酸、泛酸、氯化钠为原料,柠檬酸、山梨酸钾为辅料;共1种原料,7种营养强化剂,2种辅料组成。最佳取值范围是每5000ml饮料中含葡萄糖:200g、牛磺酸:2.5g、维生素B1:15mg、维生素B6:7.5mg、维生素B12:9mg、烟酸:75mg、泛酸:10mg、氯化钠:5g。各种成分的重量取值范围可以控制在最佳取值范围±15%,即每5000ml饮料中含葡萄糖170g-230g、牛磺酸:2.125g-2.875g、维生素B1:12.75mg-17.25mg、维生素B6:6.375mg-8.625mg、维生素B12:7.65mg-10.35mg、烟酸63.75mg-86.25mg、泛酸8.5mg-11.5mg、氯化钠4.25g-5.75g。
一.本配方的各味成分含量:
葡萄糖:葡萄糖(Glucose)(化学式C6H12O6)又称为玉米葡糖、玉蜀黍糖,简称为葡糖。英文别名:Dextrose,Cornsugar,Grapesugar,Bloodsugar。是自然界分布最广且最为重要的一种单糖,它是一种多羟基醛。纯净的葡萄糖为无色晶体,有甜味但甜味不如蔗糖(一般人无法尝到甜味),易溶于水,微溶于乙醇,不溶于乙醚。水溶液旋光向右,故属于“右旋糖”。葡萄糖在生物学领域具有重要地位,是活细胞的能量来源和新陈代谢中间产物,即生物的主要供能物质。口服后迅速吸收,进入人体后被组织利用,也可转化成糖原或脂肪贮存。正常人体每分钟利用葡萄糖的能力为每公斤体重6毫克。是一种能直接吸收利用,补充热能的碳水化合物,是人体所需能量的主要来源,在体内被氧化成二氧化碳和水,并同时供给热量,或以糖原形式贮存。能促进肝脏的解毒功能,对肝脏有保护作用。是生物体内最为常见的能源物资。本发明每5000ml饮料含200g葡萄糖,占总量的4%,接近于临床常规应用的5%葡萄糖注射液。
牛磺酸:牛磺酸(Taurine)又称β-氨基乙磺酸,最早由牛黄中分离出来,故得名。是一种含硫的非蛋白氨基酸,在体内以游离状态存在,不参与体内蛋白的生物合成。牛磺酸虽然不参与蛋白质合成,但它却与胱氨酸、半胱氨酸的代谢密切相关。人体合成牛磺酸的半胱氨酸亚硫酸羧酶(CSAD)活性较低,主要依靠摄取食物中的牛磺酸来满足机体需要。牛磺酸广泛分布于动物组织细胞内,机体可以从膳食中摄取或自身合成牛磺酸,动物性食品是膳食牛磺酸的主要来源,尤其是海生动物。体内合成是从含硫氨基酸(半胱氨酸、甲硫氨酸等)经一系列酶促反应转化而来,但自身合成能力较低。牛磺酸的分子量较小(125.1),无抗原性,各种途径给药均易吸收。牛磺酸具有多种生理功能,是人体健康必不可少的一种营养素。
维生素B1:又称硫胺素或抗神经炎素。由嘧啶环和噻唑环结合而成的一种B族维生素。为无色结晶体,溶于水,在酸性溶液中很稳定,在碱性溶液中不稳定,易被氧化和受热破坏。维生素B1主要存在于种子的外皮和胚芽中,如米糠和麸皮中含量很丰富,在酵母菌中含量也极丰富。瘦肉、白菜和芹菜中含量也较丰富。女性缺乏维生素B1的原因及症状:硫胺素在体内先经磷酸化成焦磷酸硫胺素,后者作为辅酶参与糖代谢中丙酮酸、α酮戊二酸的氧化脱羧作用,亦参与磷酸戊糖旁路的酮基移换作用。硫胺素的缺乏不仅影响糖代谢,亦涉及脂肪酸及能量代谢,使组织中出现丙酮酸、乳酸的堆积。此外脑细胞内丙氨酸产生过多而天冬氨酸、谷氨酸、γ-氨基丁酸生成减少皆为各系统导致功能障碍的生化基础。女性缺乏维生素B1易发生下列问题:①皮肤问题:色斑、湿疹、痤疮、脚气;②妇科问题:月经失调、痛经、阴道炎;③长期使用电脑的女性尤其应该注意补充维生素B1,维生素B1严重缺乏时,所有的细胞同样受损,首先出现异常症状的一定是心脏,维生素B1缺乏时,心脏异常,心跳变慢,变快,扩大。
维生素B6:维生素B6(Vitamin B6)又称吡哆素,其包括吡哆醇、吡哆醛及吡哆胺,在体内以磷酸酯的形式存在,是一种水溶性B族维生素,遇光或碱易破坏,不耐高温。1936年定名为维生素B6。维生素B6为无色晶体,易溶于水及乙醇,在酸液中稳定,在碱液中易破坏,吡哆醇耐热,吡哆醛和吡哆胺不耐高温。维生素B6在酵母菌、肝脏、谷粒、肉、鱼、蛋、豆类及花生中含量较多。维生素B6为人体内某些辅酶的组成成分,参与多种代谢反应,尤其是和氨基酸代谢有密切关系。临床上应用维生素B6制剂防治妊娠呕吐和放射病呕吐。一般而言,人的肠道中微生物(细菌)可合成维生素B6,但其量甚微,还是要从食物中补充。其需要量其实与蛋白质摄食量多寡很有关系,若吃大鱼大肉者,应记住要大量补充维生素B6,以免造成维生素B6缺而导致慢性病的发生。每日维生素B6摄入量为:成人男性2.0mg、女性1.6mg,妊娠2.2mg,哺乳2.1mg,婴儿0.3~0.6mg,11岁以下1.0~1.4mg最大使用量为4-50mg,毒性剂量未知。
维生素B12:(Vitamin B12)为B族维生素之一又称钴胺素或氰钴素。是一种由含钴的卟啉类化合物组成的B族维生素,是一类含钴的复杂有机化合物。分子结构是以钴离子为中心的咕啉环和5,6-二甲基苯并咪唑为碱基组成的核苷酸。化学式为C63H88O14N14PCo。最初发现服用全肝可控制恶性贫血症状,经20年研究,到1948年才从肝脏中分离出一种具有控制恶性贫血效果的红色晶体物质,定名为维生素B12。B12是几种变位酶的辅酶,如催化Glu转变为甲基Asp的甲基天冬氨酸变位酶、催化甲基丙二酰CoA转变为琥珀酰CoA的的甲基丙二酰CoA变位酶。B12辅酶也参与甲基及其他一碳单位的转移反应。B12主要存在于肉类中,植物中的大豆以及一些草药也含有B12,肠道细菌可以合成,故一般情况下不缺乏,但B12是消化道疾病者容易缺乏的维生素,也是红血球生成不可缺少的重要元素,如果严重缺乏,将导致恶性贫血!
烟酸:烟酸也称作维生素B3,或维生素PP,分子式:C6H5NO2。它是人体必需的13种维生素之一,是一种水溶性维生素,属于维生素B族。烟酸在人体内转化为烟酰胺,烟酰胺是辅酶I和辅酶II的组成部分,参与体内脂质代谢,组织呼吸的氧化过程和糖类无氧分解的过程。烟酸为维生素B复合物之一作为抗癞糙皮病因子而起作用,只要摄取色氨酸含量丰富的蛋白质就不会发生烟酸缺乏症。在植物和细菌里通过天门冬氨酸与C3甘油代谢物缩合而生成在人体内变为烟酰胺或经烟酸、腺嘌呤二核苷酸而成为NAD、NADP的组成成分。烟酸主要变成N′-甲基烟酰胺N′-甲基-4-吡啶酮N′-甲基-6吡啶酮被排至尿中。
泛酸:泛酸也称作维生素B5、遍多酸,无臭,味微苦,分子式为C9H17O5N。泛酸为淡黄色粘稠状物质,溶于水和醋酸,因其性质偏酸性并广泛存于多种食物中,故而得名。一般公认泛酸与头发、皮肤的营养状态密切相关,当头发缺乏光泽或变得较稀疏时,多补充泛酸可见其效;制造抗体也是泛酸的作用之一,能帮助人体抵抗传染病,缓和多种抗生素副作用及毒性,减轻过敏症状。泛酸缺乏易引起血液及皮肤异常,产生低血糖等症。
氯化钠:分子式NaCl。食盐的主要成分。我们知道食盐的主要成分就是氯化钠,这是人们生活中最常用的一种调味品。但是它的作用绝不仅仅是增加食物的味道,它是人体组织中的一种基本成分,对保证体内正常的生理、生化活动和功能,起着重要作用。
二.中医理论依据以及各味成分的作用:
葡萄糖:葡萄糖是生物体内新陈代谢不可缺少的营养物质。它的氧化反应放出的热量是人类生命活动所需能量的重要来源,工业上还大量用葡萄糖为原料合成维生素C(抗坏血酸)。葡萄糖是人体重要营养成分和主要的热量来源之一,每1克葡萄糖可产生4kcal(16.7kJ)热能。5%葡萄糖液虽系等渗液,但迅速被氧化成二氧化碳和水,因此主要用于补充水和糖分,而不是为了扩容。25%以上的高渗葡萄糖液为机体所需能量的主要来源,在体内被氧化成二氧化碳和水并同时供给热量,或以糖原形式贮存,能促进肝脏的解毒功能,对肝脏有保护作用。药理作用:能补充体内水分和糖分,具有补充体液、供给能量、补充血糖、强心利尿、解毒等作用。适应症:其5%溶液为等渗液,用于各种急性中毒,以促进毒物排泄;10%~50%为高溶液,用于低血糖症、营养不良,或用于心力衰竭、脑水肿、肺水肿等的治疗。葡萄糖作为非处方药主要用于:(1)配制口服补盐液以调节体液,用于出汗、呕吐、腹泻引起的体液丢失。(2)口服给药用于身体虚弱、营养不良等以补充营养,或用于血糖过低者。
牛磺酸:我国牛磺酸主要用于医药,作为食品营养虽然逐步被国人所认识与接受,但国人消费牛磺酸的量还非常少。世界主要一些国家人均年消费牛磺酸量大致为:日本60g、美国50g、英国34g、德国32g、加拿大29g、法国26g、韩国19g、印尼17g、新加坡17g,而我国不足0.2g。牛磺酸作为一种保健品还是比较安全的,服用一些含牛磺酸的制品,用于日常保健,还是很可取的。牛磺酸作为一种优质的营养素,应该更好地被国人利用。牛磺酸是一种特殊的氨基酸,是人体必不可少的一种营养元素,有着平衡健康的奇妙功效,牛磺酸占视网膜中游离氨基酸总量的50%,动物实验证明,缺乏牛磺酸的猫其视网膜电图显示杆细胞与锥细胞广泛变性。除了眼睛之外,牛磺酸还对其它器官有重要功效。例如,经过研究证实,人体心脏中牛磺酸含量最高。牛磺酸是通过保护心肌而增强心脏功能的。当心肌细胞中钙离子流入量过高时,就会引发冠心病。牛磺酸可以调整心肌细胞中钙离子的量,维持其平衡,实现强心。牛磺酸与心脏的关系已成为全世界重点研究的课题之一。此外,牛磺酸对肺、肝脏、胃肠等都有保护作用。在日常生活方面,牛磺酸最显著的作用就在于增强免疫力和抗疲劳。牛磺酸可以结合白细胞中的次氯酸并生成无毒性物质,降低次氯酸对白细胞自身的破坏,从而提高人体免疫力。同时,牛磺酸能维持心脏功能,使血液循环正常化,从而消除疲劳生成物,使肌体能有效地产生能量。体内保持恒定的牛磺酸,便能有效地消除疲劳,这是维持人体健康的重要因素。
维生素B1:维生素B1被称为精神性的维生素,这是因为维生素B1对神经组织和精神状态有良好的影响;在体内,维生素B1以辅酶形式参与糖的分解代谢,有保护神经系统的作用,还能促进肠胃蠕动,增加食欲。和所有B族中的维生素一样,多余的B1不会贮藏于体内,而会完全排出体外,所以,必须每天补充,成人的建议每日摄取量是1.0~1.5mg。每日摄取适量的维生素B1可促进成长;帮助消化,特别是碳水化合物的消化;改善精神状况;维持神经组织、肌肉、心脏活动的正常;减轻晕机、晕船;可缓解有关牙科手术后的痛;有助于对带状疱疹的治疗。
维生素B6:是人体脂肪和糖代谢的必需物质。维生素B6主要以磷酸吡多醛(PLP)形式参与近百种酶反应。多数与氨基酸代谢有关:包括转氨基、脱羧、侧链裂解、脱水及转硫化作用。维生素B6具有很好的安定神经的作用。维生素B6能够在多种神经递质中发挥作用,多种功能性多肽类物质的合成都需要维生素B6的参与帮助,能够帮助平衡脑细胞,安定神经兴奋状态。维生素B6还能帮助机体维持正常的免疫功能。特别是对于人体的体液免疫、细胞免疫能够产生积极影响。维生素B6能够帮助甲硫氨酸代谢物进行循环,排出体外,有效防止心血管疾病发生。维生素B6可加速身体的血液循环,改善身体出现的皮肤、头发问题。
维生素B12:属于B族维生素群中的一种。由于它也是属于水溶性维生素,是需要每天进行补充的。要注意的是人体对于维生素B12的需求量并不大,只需要在每日的膳食中注意摄入即可。尽管人体对维生素B12的需求量不大,但是维生素B12却对人体有着重要的作用:能够有效促进人体合成蛋白质,除此之外,身体中脂肪、糖类的代谢中酶的作用也需要维生素B12来参与作用;维生素B12能够有效缓解身体出现的疲劳困扰,帮助提神,抑制神经的异常兴奋,增强体力;身体充足的维生素B12能够使脂肪、碳水化合物、蛋白质正确地被身体吸收利用,帮助人增强记忆力,集中注意力,有效改善身体出现的感觉异常、记忆力减退、老年人痴呆等等,还能够帮助促进红血球的形成和再生,还能帮助促进红细胞发育成熟,这样能够有效预防身体出现恶性贫血。
烟酸:烟酸也称作维生素B3或维生素PP分子式C6H5NO2耐热能升华。它是人体必需的13种维生素之一是一种水溶性维生素属于维生素B族。烟酸在人体内转化为烟酰胺烟酰胺是辅酶I和辅酶II的组成部分参与体内脂质代谢组织呼吸的氧化过程和糖类无氧分解的过程。烟酸有较强的扩张周围血管作用临床用于治疗头痛、偏头痛、耳鸣、内耳眩晕症等。烟酸可用于防治糙皮病等烟酸缺乏病,也用作血管扩张药治疗高脂血症,治疗血管性偏头痛、头痛、脑动脉血栓形成、肺栓塞、内耳眩晕症、冻伤、中心性视网膜脉络膜炎等;对于严格控制或选择饮食或接受肠道外营养的病人因营养不良体重骤减者烟酸需要量均增加,对于体力消耗突然加大者,应适量补充烟酸。
泛酸:属于13种维生素之一。泛酸的一个重要作用是以乙酰辅酶泛酸A的形式参加代谢过程,是二碳单位的载体,也是体内乙酰化酶的辅酶,它是酰基的传递者;泛酸可帮助细胞的形成,维持正常发育和中枢神经系统的发育;泛酸具制造抗体功能,能帮助抵抗传染病,缓和多种抗生素副作用及毒性,并有助于减轻过敏症状;泛酸在维护头发、皮肤及血液健康方面有重要作用,当头发缺乏光泽或变得较稀疏时,多补充泛酸可见其效。泛酸对恢复体能有着较为明显的作用:制造及更新身体组织,缓和多种抗生素副作用及毒素,舒缓经前综合症,缓和恶心症状,帮助伤口愈合,防止疲劳,帮助抗压。
氯化钠:其最主要的作用是控制细胞、组织液和血液内的电解质平衡,以保持体液的正常流通和控制体内的酸碱平衡。Na+与K+、Ca2+、Mg2+还有助于保持神经和肌肉的适当应激水平;NaCl和KCl对调节血液的适当粘度或稠度起作用;胃里开始消化某些食物的酸和其他胃液、胰液及胆汁里的助消化的化合物,也是由血液里的钠盐和钾盐形成的。此外,适当浓度的Na+、K+和Cl-对于视网膜对光反应的生理过程也起着重要作用。可见,人体的许多重要功能都与Na+、Cl-和K+有关,体内任何一种离子的不平衡(多或少),都会对身体产生不利影响。如运动过度,出汗太多时,体内的Na+、Cl-和K+大为降低,就会出现不平衡,使肌肉和神经反应受到影响,导致恶心、呕吐、衰竭和肌肉痉挛等现象。因此,运动员在训练或比赛前后,需喝特别配制的饮料,以补充失去的盐分。由于新陈代谢,人体内每天都有一定量的Na+、Cl-和K+从各种途径排出体外,因此需要膳食给予补充,,正常成人每天氯化钠的需要量和排出量大约为3g~9g。此外,常用淡盐水漱口,不仅对咽喉疼痛、牙龈肿疼等口腔疾病有治疗和预防作用,还具有预防感冒的作用。
三.生产工艺:
以水、食用葡萄糖为原料,添加营养强化剂牛磺酸、维生素B1、维生素B6、维生素B12、烟酸、泛酸、氯化钠为辅料,并添加适量的柠檬酸、山梨酸钾,经调配、杀菌、灌装制成得。
本产品的优点:
葡萄糖人体必须的能量根本。当人们在脑力或体力劳动时,会出现困乏和劳累,若能及时补充适量的葡萄糖,它会快速进入人体成为血糖,正常人每100ml血液中含葡萄糖80~120mg,血糖随血液输送到机体细胞中,通过有氧呼吸,转化为人体脑力及体力劳动的能量。因此,葡萄糖又被称为“人体源动力”。
本发明以葡萄糖为原料,并添加营养强化剂牛磺酸、维生素B1、维生素B6、维生素B12、烟酸、泛酸、氯化钠,可快速补充人体因长时间工作、剧烈运动、身体虚弱以及夏季大量出汗所缺失各种能量,对缓解身体疲惫感有着明显的作用。
具体实施方式
本发明以快速补充体能的各种微量元素为原料,是一种能够快速补充体能的安全性和健康性更完善的新型功能性饮品。
本发明按照陕西省卫生和计划生育委员会批准的
Q/JST0002S-2016《食品企业产品标准》进行加工,其中各种配料分别按照以下国家标准或行业标准进行使用:
食用葡萄糖符合《中华人民共国国家标准》GB/T20880的规定
牛磺酸符合《中华人民共国国家标准》GB14759的规定
维生素B1符合《中华人民共国国家标准》GB14751的规定
维生素B6符合《中华人民共国国家标准》GB14753的规定
维生素B12符合《中华人民共国药典》2015年版二部的规定
烟酸符合《中华人民共国国家标准》GB14757的规定
泛酸符合《中华人民共国药典》2015年版四部的规定
氯化钠符合《中华人民共国国家标准》GB5461或GB2721的规定
以5000ml成品为例,生产工序如下
原料:葡萄糖200g
营养强化剂:牛磺酸(2.5g)、维生素B1(15mg)、维生素B6(7.5mg)、维生素B12(9mg)、烟酸(75mg)、泛酸(10mg)、氯化钠5g
食品添加剂:柠檬酸(2g)、山梨酸钾(2g)
制样流程:
1、5000ml纯净水加热至沸腾,待用;
2、氯化钠、葡萄糖分别以80℃±2纯净水(1∶50)溶解,待用;
3、各种营养强化剂分别以50℃±2纯净水(1∶50)溶解,待用;
4、柠檬酸、山梨酸钾分别以70℃±2纯净水(1∶50)溶解,待用
5、沸腾的纯净水降温至80℃±2投入牛磺酸、烟酸、泛酸;
6、沸腾的纯净水降温至70℃±2投入柠檬酸、山梨酸钾;
7、沸腾的纯净水降温至50℃±2投入维生素B1、维生素B6、维生素B12,
8、将料液从提取车间通过料液专用管道输入浓配罐,输入稀配罐,补液至5000ml,料液经高温瞬时灭菌机后,经冷却机,降温至75℃±5℃,以CGF28-28-28冲洗/灌装/封口三合一灌装机灌装、封口、灯检套标,经检验合格得成品。
下面是本产品的营养成分表:
补充体能饮料营养成分表
项目 | 每100g | 营养素参考值% |
能量 | 86kJ | 1% |
蛋白质 | 0g | 0% |
脂肪 | 1.0g | 2% |
碳水化合物 | 2.9g | 1% |
钠 | 300mg | 15% |
维生素B1 | 0.10mg | 7% |
维生素B6 | 0.05mg | 4% |
维生素B12 | 0.07mg | 3% |
烟酸 | 0.37mg | 3% |
泛酸 | 0.14mg | 3% |
牛磺酸 | 25mg | 0.5% |
Claims (3)
1.一种补充体能饮料,其特征在于:它是以葡萄糖、牛磺酸、维生素B1、维生素B6、维生素B12、烟酸、泛酸、氯化钠为原料,柠檬酸、山梨酸钾为辅料;共1种原料,7种营养强化剂,2种辅料。
2.根据权利要求1所述的一种补充体能饮料,其特征在于:所述的饮料中各味成分的最佳重量为每5000ml含葡萄糖:200g、牛磺酸:2.5g、维生素B1:15mg、维生素B6:7.5mg、维生素B12:9mg、烟酸:75mg、泛酸:10mg、氯化钠:5g。
3.根据权利要求1或者2之一所述的一种补充体能饮料,其特征在于:所述的各种成分的重量取值范围可以控制在最佳取值范围的±15%,即每5000ml饮料中含葡萄糖170g-230g、牛磺酸:2.125g-2.875g、维生素B1:12.75mg-17.25mg、维生素B6:6.375mg-8.625mg、维生素B12:7.65mg-10.35mg、烟酸63.75mg-86.25mg、泛酸8.5mg-11.5mg、氯化钠4.25g-5.75g。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201610931623.XA CN108013299A (zh) | 2016-10-31 | 2016-10-31 | 补充体能饮料 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201610931623.XA CN108013299A (zh) | 2016-10-31 | 2016-10-31 | 补充体能饮料 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN108013299A true CN108013299A (zh) | 2018-05-11 |
Family
ID=62069751
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201610931623.XA Pending CN108013299A (zh) | 2016-10-31 | 2016-10-31 | 补充体能饮料 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN108013299A (zh) |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN109566947A (zh) * | 2018-12-29 | 2019-04-05 | 安徽草珊瑚生物科技有限公司 | 一种葡萄糖电解质固体饮料 |
CN112167495A (zh) * | 2020-10-15 | 2021-01-05 | 吉源(淮北)食品科技有限公司 | 一种营养强化型抗疲劳电解质固体饮料及其制备方法 |
CN112515065A (zh) * | 2020-10-29 | 2021-03-19 | 四川工大西南食品研究有限责任公司 | 一种绿芦笋运动饮料及其制备方法 |
CN112715805A (zh) * | 2020-12-30 | 2021-04-30 | 重庆麦克渝生制药有限公司 | 一种葡萄糖营养素饮品及其制备方法 |
CN116076644A (zh) * | 2023-03-16 | 2023-05-09 | 中国人民解放军陆军军医大学 | 一种对高温环境中机体心血管有保护作用的固体饮料 |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1238925A (zh) * | 1999-04-30 | 1999-12-22 | 陈剑 | 补汗饮料 |
CN1853513A (zh) * | 2005-04-29 | 2006-11-01 | 任发政 | 一种具有缓解体力疲劳作用的运动饮料 |
US20090246322A1 (en) * | 2008-03-06 | 2009-10-01 | John David Lincoln | Trace mineral-infused beverage to provide increased athletic performance, long-lasting energy, and health benefits |
CN104509919A (zh) * | 2013-09-30 | 2015-04-15 | 张自力 | 一种功能性营养素饮料 |
-
2016
- 2016-10-31 CN CN201610931623.XA patent/CN108013299A/zh active Pending
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1238925A (zh) * | 1999-04-30 | 1999-12-22 | 陈剑 | 补汗饮料 |
CN1853513A (zh) * | 2005-04-29 | 2006-11-01 | 任发政 | 一种具有缓解体力疲劳作用的运动饮料 |
US20090246322A1 (en) * | 2008-03-06 | 2009-10-01 | John David Lincoln | Trace mineral-infused beverage to provide increased athletic performance, long-lasting energy, and health benefits |
CN104509919A (zh) * | 2013-09-30 | 2015-04-15 | 张自力 | 一种功能性营养素饮料 |
Non-Patent Citations (1)
Title |
---|
刘洪 等: "功能饮料现状及新品开发", 《饮料工业》 * |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN109566947A (zh) * | 2018-12-29 | 2019-04-05 | 安徽草珊瑚生物科技有限公司 | 一种葡萄糖电解质固体饮料 |
CN112167495A (zh) * | 2020-10-15 | 2021-01-05 | 吉源(淮北)食品科技有限公司 | 一种营养强化型抗疲劳电解质固体饮料及其制备方法 |
CN112515065A (zh) * | 2020-10-29 | 2021-03-19 | 四川工大西南食品研究有限责任公司 | 一种绿芦笋运动饮料及其制备方法 |
CN112715805A (zh) * | 2020-12-30 | 2021-04-30 | 重庆麦克渝生制药有限公司 | 一种葡萄糖营养素饮品及其制备方法 |
CN116076644A (zh) * | 2023-03-16 | 2023-05-09 | 中国人民解放军陆军军医大学 | 一种对高温环境中机体心血管有保护作用的固体饮料 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN108013299A (zh) | 补充体能饮料 | |
CN100502692C (zh) | 一种体力恢复保健食品及其制备方法 | |
US10842839B2 (en) | Natural formulation for treating hangover | |
CN103211259B (zh) | 一种抗疲劳维生素保健饮料及其制备方法 | |
US20030143311A1 (en) | Recovery drink formula and method | |
US20020119933A1 (en) | Compositions and methods for improving cardiovascular function | |
CN104509919A (zh) | 一种功能性营养素饮料 | |
CN101049150B (zh) | 有广泛用途的食用营养保健钾盐 | |
ZA200104738B (en) | Composition for optimizing muscle performance during exercise. | |
BR0011277B1 (pt) | bebida desportiva compreendendo micronutrientes em combinação com aditivos convencionais para bebidas desportivas, tablete para a preparação de uma bebida desportiva e uso de lactobacilos. | |
CN101248873A (zh) | 具有视力保护功能的饮用食品 | |
CN102160664A (zh) | 儿童营养饮料 | |
CN101461531A (zh) | 一种新型脑营养保健饮料 | |
CN103190483A (zh) | 儿童成长奶茶 | |
CN110447796A (zh) | 一种醒酒护肝的饮料及其制备方法 | |
CN104855975A (zh) | 肌肉衰减综合征非全营养配方食品 | |
CN109527313A (zh) | 一种可缓解视觉和体力疲劳的功能性饮料及其制备方法 | |
US20030104107A1 (en) | Energy drink formula and method | |
CN104856000A (zh) | 失眠非全营养配方食品 | |
CN103126026B (zh) | 一种解酒饮料及制备方法 | |
CN105454944A (zh) | 一种人参饮料及其制备方法 | |
CN112772809A (zh) | 一种运动训练专用饮料及其制备方法 | |
WO2005087022A1 (ja) | 抗ストレス作用を有する食品組成物 | |
CN107485619A (zh) | 一种b族维生素复合物及其制备方法 | |
CN103621871B (zh) | 一种复合氨基酸保健品及其制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20180511 |
|
RJ01 | Rejection of invention patent application after publication |